Estalis Continuous 50/250 is a medicine containing the active ingredient(s) estradiol + norethisterone acetate. On this page you will find out more about Estalis Continuous 50/250, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: estradiol + norethisterone acetate
Information for medicine and pack size:
Estalis Continuous 50/250 patch, 8
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
For the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. For prevention of postmenopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for non-oestrogen products approved for prevention of bone mineral density loss. Lifestyle modifications and the risk-benefit profile of Estalis Continous should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing. Combination HRT should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.
Table of characteristics
|Visual appearance||An off-white translucent patch with a removable pre-cut liner: 16cm2 round patch.|
|Dosage Form||Drug delivery system, transdermal|
|Route of administration||Transdermal|
2 patches sample pack: Prescription Only Medicine, or Prescription Animal Remedy
8 patches: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||Do not Freeze,Refrigerate|
|Life time||30 Months|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 March 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.